Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

RxSight (RXST) Gross Margin (2020 - 2026)

RxSight filings provide 6 years of Gross Margin readings, the most recent being 77.47% for Q4 2025.

  • On a quarterly basis, Gross Margin rose 589.0% to 77.47% in Q4 2025 year-over-year; TTM through Dec 2025 was 76.6%, a 589.0% increase, with the full-year FY2025 number at 76.6%, up 589.0% from a year prior.
  • Gross Margin hit 77.47% in Q4 2025 for RxSight, down from 79.85% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 79.85% in Q3 2025 to a low of 16.58% in Q2 2021.
  • Median Gross Margin over the past 5 years was 60.52% (2023), compared with a mean of 53.79%.
  • Biggest five-year swings in Gross Margin: surged 94bps in 2021 and later soared 5873bps in 2022.
  • RxSight's Gross Margin stood at 34.05% in 2021, then surged by 35bps to 46.13% in 2022, then soared by 34bps to 61.77% in 2023, then grew by 16bps to 71.59% in 2024, then grew by 8bps to 77.47% in 2025.
  • The last three reported values for Gross Margin were 77.47% (Q4 2025), 79.85% (Q3 2025), and 74.89% (Q2 2025) per Business Quant data.